ArticleJournal of fluorescence2025
Microfluidic Platform for Predicting Nanoparticle Dynamics in Cancer Therapeutics.
Article in Journal of fluorescence, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this study was to design a simple microfluidic tumor-on-a-chip representation for investigating nanoparticle (NP) penetration and envisaging their behaviour for cancer treatment by utilizing synthetic Yellow-Green FluoSphere NPs (40 nm) and 200 nm Red FluoSphere NPs. This method is not only convenient but cost effective too and can easily be adapted for different types of cancer. Moreover, silver nanoparticles (AgNPs) were also synthesized (green) via B. subtilis (BTCB12) through the assistance of microfluidics to inspect cell viability (%) utilizing MCF7 carcinoma (breast cancer cells) in conjunction with AgNPs on and off chip. Prior to any experimentation, both synthetic and green NPs were subjected to characterization utilizing Dynamic Light Scattering (DLS) that measured the size of the NPs whereas the zeta potential analysis disclosed stability of both types of NPs. Additionally, UV-Vis spectrophotometer evaluated the excitation peaks at 500 nm and 590 nm with Yellow-Green NPs and Red NPs respectively while AgNPs exhibited it at 400 nm. Afterwards FTIR also revealed some functional groups with FluoSpheres and AgNPs. Nevertheless, X-ray diffraction (XRD) studies revealed crystalline nature of AgNPs and Transmission Electron Microscopy (TEM) displayed spherical AgNPs. After construction of the device it was at first loaded with synthetic NPs to observe their penetration intensity (%) and interactions using Fluorescence Microscopy. It was noted that Red FluoSpheres had less penetration intensity of 42 ± 1.07% than Yellow-Green FluoSpheres 49 ± 2.12%. Later cell viability with MCF7 carcinoma (breast cancer cells) and AgNPs was studied. MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay (off-chip) demonstrated highest cell viability at 35 ± 1.10% with 2:1 whereas on-chip experiments presented it at 30 ± 0.09% with 100 µM concentration of AgNPs as verified by Live/dead kit. These treatments appear promising involving various NP formulations that can be applied to cancer cells during chemotherapy and related applications.
Indexed as
Identifiers
40788556What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.